BR112015005351A2 - sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior - Google Patents

sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior

Info

Publication number
BR112015005351A2
BR112015005351A2 BR112015005351A BR112015005351A BR112015005351A2 BR 112015005351 A2 BR112015005351 A2 BR 112015005351A2 BR 112015005351 A BR112015005351 A BR 112015005351A BR 112015005351 A BR112015005351 A BR 112015005351A BR 112015005351 A2 BR112015005351 A2 BR 112015005351A2
Authority
BR
Brazil
Prior art keywords
bladder
methods
drug delivery
trospium
delivery systems
Prior art date
Application number
BR112015005351A
Other languages
English (en)
Portuguese (pt)
Inventor
Giesing Dennis
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of BR112015005351A2 publication Critical patent/BR112015005351A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
BR112015005351A 2012-09-18 2013-09-18 sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior BR112015005351A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702576P 2012-09-18 2012-09-18
PCT/US2013/060479 WO2014047221A1 (en) 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium

Publications (1)

Publication Number Publication Date
BR112015005351A2 true BR112015005351A2 (pt) 2017-07-04

Family

ID=49301639

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005351A BR112015005351A2 (pt) 2012-09-18 2013-09-18 sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior

Country Status (13)

Country Link
US (2) US10500200B2 (https=)
EP (1) EP2897616A1 (https=)
JP (2) JP6600256B2 (https=)
KR (1) KR102141433B1 (https=)
CN (2) CN104684556A (https=)
AU (1) AU2013318146B2 (https=)
BR (1) BR112015005351A2 (https=)
CA (1) CA2883855C (https=)
IL (1) IL237498B (https=)
MX (2) MX379066B (https=)
RU (1) RU2670749C9 (https=)
SG (1) SG11201502104YA (https=)
WO (1) WO2014047221A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
SG11201501424SA (en) 2012-08-31 2015-03-30 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX379066B (es) * 2012-09-18 2025-03-04 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior.
LT4124339T (lt) 2014-03-06 2025-11-10 Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu
CN106573133B (zh) * 2014-08-19 2020-03-03 加利福尼亚大学董事会 用于局部药物递送的植入物及其使用方法
GB201506526D0 (en) 2015-04-17 2015-06-03 Uropharma Ltd And Synesis Llc Medicinal composition
CN106706832A (zh) * 2015-08-06 2017-05-24 舒泰神(北京)生物制药股份有限公司 一种测定曲司氯铵含量的方法
PT3432970T (pt) 2017-02-01 2021-05-26 Taris Biomedical Llc Dispositivos de administração de fármaco in vivo
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法
WO2019217455A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CN112839653A (zh) * 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
AU2020265812B2 (en) * 2019-04-30 2025-08-28 Trigone Pharma Ltd. Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
JP7665645B2 (ja) 2020-03-20 2025-04-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 局所的な薬物送達のための移植可能な薬物送達デバイス
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
KR102596697B1 (ko) 2021-05-20 2023-11-01 김정우 바위솔 추출물을 유효성분으로 포함하는 화장품 조성물 및 그 제조 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2125696T3 (es) * 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US20060058777A1 (en) * 2002-12-11 2006-03-16 Pia Norup Nielsen Urinary catheter device with a pharmaceutically active composition
WO2004064789A2 (en) 2003-01-16 2004-08-05 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
ES2322148T3 (es) 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
WO2006101954A2 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
DK1933810T3 (da) 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
KR101538748B1 (ko) 2007-12-11 2015-07-22 메사추세츠 인스티튜트 오브 테크놀로지 이식형 의약 투여 장치와 방광과 기타 신체 낭 또는 내강의 치료 방법
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
DK2445570T3 (da) 2009-06-26 2013-02-25 Taris Biomedical Inc Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
PL3884988T3 (pl) 2009-12-17 2025-09-08 Taris Biomedical Llc Urządzenie implantowalne z tolerancją wewnątrzpęcherzową
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
WO2012048114A1 (en) * 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル,インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
EP2670398B1 (en) * 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
MX379066B (es) * 2012-09-18 2025-03-04 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior.
KR102557326B1 (ko) 2013-03-15 2023-07-19 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치

Also Published As

Publication number Publication date
JP2015529688A (ja) 2015-10-08
CA2883855C (en) 2020-09-15
JP6600256B2 (ja) 2019-10-30
IL237498B (en) 2018-01-31
CN111450093A (zh) 2020-07-28
CA2883855A1 (en) 2014-03-27
IL237498A0 (en) 2015-04-30
RU2015112196A (ru) 2016-11-10
MX2020002465A (es) 2020-07-13
WO2014047221A9 (en) 2015-05-21
SG11201502104YA (en) 2015-05-28
JP2018080208A (ja) 2018-05-24
WO2014047221A1 (en) 2014-03-27
EP2897616A1 (en) 2015-07-29
AU2013318146B2 (en) 2018-05-10
RU2670749C2 (ru) 2018-10-25
KR20150058271A (ko) 2015-05-28
RU2670749C9 (ru) 2018-12-13
MX2015003110A (es) 2015-06-05
US20150182516A1 (en) 2015-07-02
CN104684556A (zh) 2015-06-03
MX379066B (es) 2025-03-04
AU2013318146A1 (en) 2015-03-19
US20200108057A1 (en) 2020-04-09
KR102141433B1 (ko) 2020-08-05
US11850244B2 (en) 2023-12-26
US10500200B2 (en) 2019-12-10

Similar Documents

Publication Publication Date Title
BR112015005351A2 (pt) sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
EP4461326A3 (en) Flexible system for delivering an anchor
EA202091999A2 (ru) Применение ингибиторов dpp iv
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
MY193694A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
WO2014075084A3 (en) Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX377897B (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
MX2010006724A (es) Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
Barsotti CMV lung infection, bladder infection and erythematous rash: 3 case reports
RU2008130241A (ru) Способ и средство для реабилитации детей с хроническими риносинуситами
FR2962900B1 (fr) Bassin de traitement par hydrotherapie de la partie inferieure du corps, application dudit bassin notamment au traitement therapeutique du corps et en particulier au traitement de la fibromyalgie.
Feito-Rodriguez Bacterial vaginosis: case report

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]